|
Novoa-Bolivar EM, Ros JA, Perez-Fernandez S, Campillo JA, Lopez-Hernandez R, Gonzalez-Lopez R, Otalora-Alcaraz A, Ortuno-Hernandez C, Gimeno L, Ruiz-Lorente I, Ceballos-Francisco D, Muro M, Solana E, Martinez-Camblor P, Minguela A. Predictive Value of Flow Cytometry Quantification of BAL Lymphocytes and Neutrophils in ILD. Cells. 2024 Dec 13;13(24):2066. doi: 10.3390/cells13242066. PubMed PMID: 39768157; PubMed Central PMCID: PMC11674578.
AÑO: 2024; IF: 5.1
|
39768157
|
Collados-Ros A, Muro M, Legaz I. Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: Efficacy, Toxicity, and Resistance Mechanisms-A Systematic Review. Biomedicines. 2024 Jan 17;12(1):208. doi: 10.3390/biomedicines12010208. PubMed PMID: 38255313; PubMed Central PMCID: PMC10813452.
AÑO: 2024; IF: 3.9
|
|
Moya-Quiles MR, Muro M. Identification of the novel HLA-C*08:291 allele by next-generation sequencing. HLA. 2024 Sep;104(3):e15689. doi: 10.1111/tan.15689. PubMed PMID: 39279454.
AÑO: 2024; IF: 5.9
|
|
Ramos Elbal E, Fuster JL, Campillo JA, Galera AM, Cortes MB, Llinares ME, Jimenez I, Plaza M, Martinez Banaclocha H, Galian JA, Blanquer Blanquer M, Martinez Sanchez MV, Muro M, Minguela A. Measurable residual disease study through three different methods can anticipate relapse and guide early interventions in childhood acute lymphoblastic leukemia. Clin Transl Oncol. 2024 Jan;26(1):278-287. doi: 10.1007/s12094-023-03251-0. Epub 2023 Jun 27. PubMed PMID: 37368200.
AÑO: 2024; IF: 2.8
|
|
Legaz I, Navarro-Noguera E, Collados-Ros A, Bolarin JM, Muro M. Biomarkers of Innate Immunity and Immunological Susceptibility to Viral Infection in Patients with Alcoholic Cirrhosis. Biomedicines. 2024 Feb 1;12(2):336. doi: 10.3390/biomedicines12020336. PubMed PMID: 38397937; PubMed Central PMCID: PMC10887413.
AÑO: 2024; IF: 3.9
|